Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial

por Seino, Hiroaki
Publicado 2021

Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial

por Seino, Hiroaki
Publicado 2021

Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis

por Seino, Hiroaki, Onishi, Yukiko, Naito, Yusuke, Komatsu, Mitsuhisa
Publicado 2016

Efficacy and Safety of 5-Aminolevulinic Acid Combined with Iron on Skeletal Muscle Mass Index and Physical Performance of Patients with Sarcopenia: A Multicenter, Double-Blinded, R...

por Tamura, Yoshifumi, Kaga, Hideyoshi, Abe, Yasuko, Yoshii, Hidenori, Seino, Hiroaki, Hiyoshi, Toru, Kuribayashi, Nobuichi, Inoue, Ikuo, Watada, Hirotaka
Publicado 2023

Current status of achieving blood pressure target and its clinical correlates in Japanese type 2 diabetes (JDDM45)

por Yokoyama, Hiroki, Araki, Shin‐ichi, Kawai, Koichi, Hirao, Koichi, Kurihara, Yoshio, Seino, Hiroaki, Takamura, Hiroshi, Sugimoto, Hidekatsu, Okada, Akira, Maegawa, Hiroshi
Publicado 2017

Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

por Nakajima, Hiroki, Okada, Sadanori, Mohri, Takako, Kanda, Eiichiro, Inaba, Naoyuki, Hirasawa, Yoko, Seino, Hiroaki, Kuroda, Hisamoto, Hiyoshi, Toru, Niiya, Tetsuji, Ishii, Hitoshi
Publicado 2018

Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inh...

por Ishihara, Hisamitsu, Anai, Motonobu, Seino, Hiroaki, Kitazawa, Toru, Ohashi, Hiroshi, Ai, Masumi, Inoue, Masahiro, Fujishiro, Midori, Inazawa, Takeshi, Kuroda, Hisamoto, Yamada, Masayo
Publicado 2018

Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase‐4 inhibitor in Japanese patients with type 2 diabetes: A rando...

por Kitazawa, Toru, Seino, Hiroaki, Ohashi, Hiroshi, Inazawa, Takeshi, Inoue, Masahiro, Ai, Masumi, Fujishiro, Midori, Kuroda, Hisamoto, Yamada, Masayo, Anai, Motonobu, Ishihara, Hisamitsu
Publicado 2020

Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study)

por Ishii, Hitoshi, Kamei, Nozomu, Shimono, Dai, Niiya, Tetsuji, Tosaki, Takahiro, Kitazawa, Toru, Suzuki, Daisuke, Wakasa, Yutaka, Seino, Hiroaki, Oishi, Mariko, Ohashi, Hiroshi, Higami, Kenshi, Akai, Hiroaki
Publicado 2023